Get started
Author

Elena Bunkova

Observed name: E. B. Bun'kova
ORCID: 0009-0005-9395-8334
Observed ORCID: 0009-0005-9395-8334
OpenAlex ID: A5069777010
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
2023 · Brian G Feagan, Bruce E Sands, et al. · The Lancet. Gastroenterology & hepatology · 267
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
2024 · David T Rubin, Jessica R Allegretti, et al. · The Lancet · 141
PDF
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
2023 · Laurent Peyrin-Biroulet, Jessica R. Allegretti, et al. · Gastroenterology · 110
PDF
A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy
2021 · Sara Montagnese, Mette Lauridsen, et al. · Journal of Hepatology · 55
PDF
Modern etiotropic therapy of chronic viral hepatitis B
2024 · E. B. Bun'kova, N. A. Bileva, et al. · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH)
PDF
The feasibility of pathogenetic therapy for chronic viral hepatitis C in adult HIV-infected patients
2024 · E. B. Bun'kova, N. A. Bileva, et al. · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH)
PDF
Works count: 6
Citation count: 573
H-index: 4
I10-index: 4
Year
Topic
Type